Utility of stereotactic ablative radiotherapy/stereotactic body radiation therapy in the setting of oligometastatic non-small cell lung cancer.
作者信息
Song Andrew, Lu Bo
机构信息
Department of Radiation Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.
出版信息
J Thorac Dis. 2018 Feb;10(2):657-660. doi: 10.21037/jtd.2018.01.22.
Abstract
摘要
相似文献
1
Utility of stereotactic ablative radiotherapy/stereotactic body radiation therapy in the setting of oligometastatic non-small cell lung cancer.立体定向消融放疗/立体定向体部放疗在寡转移非小细胞肺癌中的应用价值
J Thorac Dis. 2018 Feb;10(2):657-660. doi: 10.21037/jtd.2018.01.22.
2
Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease.立体定向消融体部放疗用于寡转移和寡进展性疾病。
Transl Lung Cancer Res. 2019 Feb;8(1):97-106. doi: 10.21037/tlcr.2018.09.21.
3
[Stereotactic body radiation radiotherapy for oligometastatic non-small cell lung cancer (NSCLC): A case report].[立体定向体部放射治疗寡转移非小细胞肺癌（NSCLC）：一例报告]
Cancer Radiother. 2015 May;19(3):192-7. doi: 10.1016/j.canrad.2014.12.007. Epub 2015 Apr 1.
4
Stereotactic Body Radiotherapy and Ablative Therapies for Lung Cancer.肺癌的立体定向体部放射治疗与消融治疗
Surg Oncol Clin N Am. 2016 Jul;25(3):553-66. doi: 10.1016/j.soc.2016.02.008.
5
6
Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.立体定向消融放疗治疗寡转移结直肠癌患者的肺转移：长期随访后的结果和预后因素
Clin Colorectal Cancer. 2017 Mar;16(1):58-64. doi: 10.1016/j.clcc.2016.07.004. Epub 2016 Jul 18.
7
Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.寡转移非小细胞肺癌的消融治疗。
Clin Lung Cancer. 2017 Nov;18(6):595-606. doi: 10.1016/j.cllc.2017.03.002. Epub 2017 Mar 14.
8
Changing equipoise in the landscape of radiation for oligometastatic lung cancer.寡转移性肺癌放疗格局中的平衡变化
Transl Lung Cancer Res. 2019 Sep;8(Suppl 2):S184-S191. doi: 10.21037/tlcr.2019.07.09.
9
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).一项关于寡转移前列腺癌观察与立体定向消融放疗对比的II期随机试验（ORIOLE）。
BMC Cancer. 2017 Jun 29;17(1):453. doi: 10.1186/s12885-017-3455-6.
引用本文的文献
1
Differences in Lung Cancer-related Clinical Practice and Basic Research Background between Japan and China: A Narrative Review.日本与中国肺癌相关临床实践及基础研究背景的差异：一篇叙述性综述
Intern Med. 2025 Sep 1;64(17):2524-2533. doi: 10.2169/internalmedicine.4808-24. Epub 2025 Mar 1.
2
Pulmonary oligometastases treated by stereotactic body radiation therapy (SBRT): a single institution's experience.立体定向体部放射治疗（SBRT）治疗肺寡转移瘤：单机构经验
Transl Lung Cancer Res. 2020 Aug;9(4):1496-1506. doi: 10.21037/tlcr-20-867.
3
Lung-molGPA Index Predicts Survival Outcomes of Non-Small-Cell Lung Cancer Patients with Synchronous or Metachronous Brain Metastases.肺分子GPA指数可预测非小细胞肺癌伴同步或异时性脑转移患者的生存结局。
Onco Targets Ther. 2020 Sep 4;13:8837-8844. doi: 10.2147/OTT.S255478. eCollection 2020.
4
Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists.立体定向消融放疗（SABR）的放射生物学：临床肿瘤学家的观点
J Cancer. 2020 Jun 27;11(17):5056-5068. doi: 10.7150/jca.44408. eCollection 2020.
本文引用的文献
1
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.局限性转移性非小细胞肺癌的巩固性放疗：一项 2 期随机临床试验。
JAMA Oncol. 2018 Jan 11;4(1):e173501. doi: 10.1001/jamaoncol.2017.3501.
2
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.Durvalumab 用于 III 期非小细胞肺癌放化疗后的治疗。
N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.
3
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.既往放疗与帕博利珠单抗治疗非小细胞肺癌的临床活性及毒性：KEYNOTE-001 1期试验的二次分析
Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24.
4
Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review.同期立体定向放疗与靶向治疗或免疫治疗的毒性：系统评价。
Cancer Treat Rev. 2017 Feb;53:25-37. doi: 10.1016/j.ctrv.2016.11.013. Epub 2016 Dec 19.
5
Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer.晚期非小细胞肺癌进展后继续抑制表皮生长因子受体
Eur J Cancer. 2017 Jan;70:12-21. doi: 10.1016/j.ejca.2016.10.014. Epub 2016 Nov 17.
6
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.一线全身治疗后无进展的寡转移性非小细胞肺癌患者的局部巩固治疗与维持治疗或观察比较：一项多中心、随机、对照、2期研究
Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24.
7
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.IASLC 肺癌分期项目：对即将发布的（第八版）肺癌 TNM 分类中 TNM 分期分组的修订建议。
J Thorac Oncol. 2016 Jan;11(1):39-51. doi: 10.1016/j.jtho.2015.09.009.
8
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).一项厄洛替尼对比化疗作为 EGFR 突变阳性晚期非小细胞肺癌一线治疗的随机 III 期研究（OPTIMAL，CTONG-0802）的最终总生存结果。
Ann Oncol. 2015 Sep;26(9):1877-1883. doi: 10.1093/annonc/mdv276. Epub 2015 Jul 3.
9
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.克唑替尼对比化疗用于治疗 ALK 阳性肺癌。
N Engl J Med. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440.
10
Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.局限进展期转移性非小细胞肺癌患者立体定向放疗联合厄洛替尼的Ⅱ期临床试验
J Clin Oncol. 2014 Dec 1;32(34):3824-30. doi: 10.1200/JCO.2014.56.7412. Epub 2014 Oct 27.
Zotero 插件